EP1735323B1 - Synthetic membrane anchors - Google Patents

Synthetic membrane anchors Download PDF

Info

Publication number
EP1735323B1
EP1735323B1 EP05722123.6A EP05722123A EP1735323B1 EP 1735323 B1 EP1735323 B1 EP 1735323B1 EP 05722123 A EP05722123 A EP 05722123A EP 1735323 B1 EP1735323 B1 EP 1735323B1
Authority
EP
European Patent Office
Prior art keywords
dope
tri
construct
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05722123.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1735323A1 (en
EP1735323A4 (en
Inventor
Nicolai Bovin
Lissa Gilliver
Stephen Henry
Elena Korchagina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kode Biotech Ltd
Original Assignee
Kode Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kode Biotech Ltd filed Critical Kode Biotech Ltd
Publication of EP1735323A1 publication Critical patent/EP1735323A1/en
Publication of EP1735323A4 publication Critical patent/EP1735323A4/en
Application granted granted Critical
Publication of EP1735323B1 publication Critical patent/EP1735323B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Definitions

  • the invention relates to synthetic molecules that spontaneously and stably incorporate into lipid bi-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these molecules as synthetic membrane anchors or synthetic molecule constructs to effect qualitative and quantitative changes in the expression of cell surface antigens.
  • Cell surface antigens mediate a range of interactions between cells and their environment. These interactions include cell-cell interactions, cell-surface interactions and cell-solute interactions. Cell surface antigens also mediate intra-cellular signalling.
  • Cells are characterised by qualitative and quantitative differences in the cell surface antigens expressed. Qualitative and quantitative changes in the cell surface antigens expressed alter both cell function (mode of action) and cell functionality (action served).
  • Protein painting is a non-transgenic method for effecting qualitative and/or quantitative changes in the surface antigens expressed by a cell.
  • the method exploits the ability of GPI linked proteins to spontaneously anchor to the cell membrane via their lipid tails.
  • the method described in the specification accompanying international application no. PCT/US98/15124 includes the step of inserting a GPI linked protein isolated from a biological source into a membrane. Isolated GPI-anchored proteins are stated as having an unusual capacity to reintegrate with a cell-surface membrane.
  • the cell membrane is a lipid bilayer that serves as a semi-permeable barrier between the cytoplasm of the cell and this aqueous environment. Localising antigens to the cell surface may also be achieved by the use of glycolipids as membrane anchors.
  • the method described in the specification accompanying international application no. PCT/NZ02/00214 includes the step of inserting a controlled amount of glycolipid into a membrane.
  • the amount of glycolipid inserted is controlled to provide cells with a desired level of antigen expression.
  • the method described in the specification accompanying international application no. PCT/NZ03/00059 includes the step of inserting a modified glycolipid into a membrane as a "membrane anchor".
  • the modified glycolipid provides for the localisation of antigens to the surface of the cell or multicellular structure. New characteristics may thereby be imparted on the cell or multicellular structure.
  • glycolipid or glycolipid-linked antigens typically include the isolation of a glycolipid or glycolipid-linked antigen from a biological source.
  • the isolation of glycolipids or glycolipid-linked antigens from biological sources is costly, variable and isolatable amounts are often limited.
  • Obtaining reagents from zoological sources for therapeutic use is particularly problematic, especially where the reagent or its derivative products are to be administered to a human subject.
  • Synthetic molecules for which the risk of contamination with zoo-pathogenic agents can be excluded are preferred. Synthetic counterparts for naturally occurring glycolipids and synthetic neo-glycolipids have been reported. However, for a synthetic glycolipid to be of use as a membrane anchor it must be able to spontaneously and stably incorporate into a lipid bi-layer from an aqueous environment. The utility of synthetic glycolipids in diagnostic or therapeutic applications is further limited to those synthetic glycolipids that will form a solution in saline.
  • Organic solvents and/or detergents used to facilitate the solubilization of glycolipids in saline must be biocompatible. Solvents and detergents must often be excluded or quickly removed as they can be damaging to some cell membranes. The removal of solvents or detergents from such preparations can be problematic.
  • Damage to cell membranes is to be avoided especially where the supply of cells or multicellular structures is limited, e.g. embryos, or the cells are particularly sensitive to perturbation, e.g. hepatocytes.
  • glycolipids and glycolipid-linked antigens isolated from biological sources would obviate the limitations of glycolipids and glycolipid-linked antigens isolated from biological sources and facilitate being able to effect qualitative and/or quantitative changes in the surface antigens expressed by a cell.
  • the preceding objects are to be read disjunctively with the object to at least provide the public with a useful choice.
  • the invention consists in a synthetic membrane anchor or synthetic molecule construct of the structure F-S 1 -S 2 -L where:
  • L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids. More preferably L is selected from the group consisting of: diacylglycerolipids, phosphatidate, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, phosphatidyl glycerol, and diphosphatidyl glycerol derived from one or more of trans- 3-hexadecenoic acid, cis -5-hexadecenoic acid, cis -7-hexadecenoic acid, cis -9-hexadecenoic acid, cis-6-octadecenoic acid, cis -9-octadecenoic acid, trans -9-octadecenoic acid, trans -11-octadece
  • the lipid is derived from one or more cis -destaurated fatty acids.
  • L is selected from the group consisting of: 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE), 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE) and rac-1,2-dioleoylglycerol (DOG).
  • DOPE 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine
  • DSPE 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine
  • DOG 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine
  • n is 3.
  • the molecule is water soluble.
  • the molecule spontaneously incorporates into a lipid bi-layer when a solution of the molecule is contacted with the lipid bi-layer. More preferably the molecule stably incorporates into the lipid bilayer.
  • F, S 1 , S 2 and L are covalently linked.
  • F is selected from the group consisting of naturally occurring or synthetic glycotopes.
  • S 1 -S 2 is selected to provide a water soluble synthetic membrane anchor or synthetic molecule construct.
  • F is a naturally occurring or synthetic glycotope.
  • F is a naturally occurring or synthetic glycotope consisting of three (trisaccharide) or more sugar units. More preferably F is a glycotope selected from the group consisting of lacto-neo-tetraosyl, lactotetraosyl, lacto-nor-hexaosyl, lacto-iso-octaosyl, globoteraosyl, globo-neo-tetraosyl, globopentaosyl, gangliotetraosyl, gangliotriaosyl, gangliopentaosyl, isoglobotriaosyl, isoglobotetraosyl, mucotriaosyl and mucotetraosyl series of oligosaccharides.
  • F is selected from the group of glycotopes comprising the terminal sugars GalNAc ⁇ l-3(Fuc ⁇ 1-2)Galß; Gal ⁇ 1-3Galß; Galß; Gal ⁇ 1-3(Fuc ⁇ 1-2)Galß; NeuAc ⁇ 2-3Galß; NeuAc ⁇ 2-6Galß; Fuc ⁇ 1-2Galß; Galß1-4GlcNAcß1-6(Galß1-4GlcNAcßA1-3)Galß; Fuc ⁇ 1-2Galß1-4GlcNAcß1-6(Fuc ⁇ 1-2Galß1-4GlcNAcß1-3)Galß ⁇ ; Fuc ⁇ 1-2Galß1-4GlcNAcß1-6(NeuAca2-3Galß1-4GlcNAcß1-3)Galß; NeuAc ⁇ 2-3Galß1-4GlcNAcß1-6(NeuAca2-3Galß1-4GlcNAcß1-3)Galß; Gal ⁇ 1-4Galß1-4Glc; GalNAcß1-3Gal ⁇ 1-4Galß1-4Gl
  • L is a glycerophospholipid and S 2 is selected from the group including: -CO(CH 2 ) 3 CO-, -CO(CH 2 ) 4 CO- (adipate), -CO(CH 2 ) 5 CO- and -CO(CH 2 ) 5 NHCO(CH 2 ) 5 CO-, preferably S 1 is a C 3-5 -aminoalkyl selected from the group consisting of: 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl. More preferably S 1 is 3-aminopropyl.
  • F is a molecule that mediates a cell-cell or cell-surface interaction.
  • F is a carbohydrate with an affinity for a component expressed on a targeted cell or surface. More preferably F has an affinity for a component expressed on epithelial cells or extra-cellular matrices. Yet more preferably F has an affinity for a component expressed on the epithelial cells or the extra-cellular matrix of the endometrium. Most preferably the component expressed on the epithelial cells or the extra-cellular matrix of the endometrium can be a naturally expressed component or an exogenously incorporated component.
  • F is a molecule that mediates a cell-solute interaction.
  • F is a ligand for a binding molecule where the presence of the binding molecule is diagnostic for a pathological condition.
  • F is a ligand for an antibody (immunoglobulin).
  • the water soluble synthetic membrane anchor or synthetic molecule construct has the structure: designated A tri -sp-Ad-DOPE (I); the structure: designated A tri -spsp 1 -Ad-DOPE (II); the structure: designated A tri -sp-Ad-DSPE (III); the structure designated B tri -sp-Ad-DOPE (VI); the structure: designated H tri -sp-Ad-DOPE (VII); the structure: designated H di -sp-Ad-DOPE (VIII); the structure: designated Galß i -sp-Ad-DOPE (IX); the structure: designated Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE (XII); or the structure: designated Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE (XIII).
  • M is typically H, but may be replaced by another monovalent cation such as Na + , K + or NH 4 + .
  • the disclosure consists in a method of preparing a synthetic membrane anchor or synthetic molecule construct of the structure F-S 1 -S 2 -L including the steps:
  • the molecule is water soluble.
  • the molecule spontaneously incorporates into a lipid bi-layer when a solution of the molecule is contacted with the lipid bi-layer. More preferably the molecule stably incorporates into the lipid bilayer.
  • F, S 1 , S 2 and L are covalently linked.
  • F is selected from the group consisting of naturally occurring or synthetic glycotopes.
  • L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids. More preferably L is selected from the group consisting of: diacylglycerolipids, phosphatidate, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, phosphatidyl glycerol, and diphosphatidyl glycerol derived from one or more of trans -3-hexadecenoic acid, cis -5-hexadecenoic acid, cis -7-hexadecenoic acid, cis -9-hexadecenoic acid, cis -6-octadecenoic acid, cis -9-octadecenoic acid, trans -9-octadecenoic acid, trans -11-octa
  • the lipid is derived from one or more cis -destaurated fatty acids.
  • L is selected from the group consisting of; 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE), 1,2-O-distearyl-sn-glycero-3-phosphatldylethanolamine (DSPE) and rac -9,2-dioleoylglycerol (DOG).
  • DOPE 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine
  • DSPE 1,2-O-distearyl-sn-glycero-3-phosphatldylethanolamine
  • DOG 1,2-O-distearyl-sn-glycero-3-phosphatldylethanolamine
  • n is 3.
  • a (R-S 2 ) and S 1 are selected to provide a water soluble synthetic molecule construct.
  • F is a naturally occurring or synthetic glycotope
  • F is a naturally occurring or synthetic glycotope consisting of three (trisaccharide) or more sugar units
  • F is a glycotope selected from the group consisting of lacto-neo-tetraosyl, lactotetraosyl, lacto-nor-hexaosyl, lacto-iso-octaosyl, globoteraosyl, globo-neo-tetraosyl, globopentaosyl, gangliotetraosyl, gangliotriaosyl, gangliopentaosyl, isoglobotriaosyl, isoglobotetraosyl, mucotriaosyl and mucotetraosyl series of oligosaccharides.
  • F is selected from the group of glycotopes comprising the terminal sugars GalNAc ⁇ 1-3(Fuc ⁇ 1-2)Galß; Gal ⁇ 1-3Galß; Galß; Gal ⁇ 1-3(Fuc ⁇ 1-2)Galß; NeuAc ⁇ 2-3Galß; NeuAc ⁇ 2-6Galß; Fuc ⁇ 1-2Galß; Galß1-4GlcNAcß1-6(Galß1-4GlcNAcß1-3)Galß; Fuc ⁇ 1-2Galß1-4GlcNAcß1-6(Fuc ⁇ 1-2Galß1-4GlcNAcß1-3)Galß; Fuc ⁇ 1-2Galß1-4GlcNAcß1-6(NeuAc ⁇ 2-3Galß1-4GlcNAcß1-3)Galß; NeuAc ⁇ 2-3Galß1-4GlcNAcß1-6(NeuAc ⁇ 2-3Galß1-4GlcNAcß1-3)Galß; Gel ⁇ 1-4Galß1-4Glc; GalNAcß1-3Gal ⁇ 1-4Galß1-4Glc
  • L is a glycerophospholipid and S 2 is selected from the group including: -CO(CH 2 ) 3 CO-, -CO(CH 2 ) 4 CO- (adipate), -CO(CH 2 ) 5 CO- and -CO(CH 2 ) 5 NHCO(CH 2 ) 5 CO-, preferably S 1 is a C 3-5 -aminoalkyl selected from the group consisting of: 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl. More preferably S 1 is 3-aminopropyl.
  • F is a molecule that mediates a cell-cell or cell-surface interaction.
  • F is carbohydrate with an affinity for a component expressed on a targeted cell or surface.
  • F has an affinity for a component expressed on epithelial cells or extra-cellular matrices.
  • F has an affinity for a component expressed on the epithelial cells or the extra-cellular matrix of the endometrium.
  • the component expressed on the epithelial cells or the extra-cellular matrix of the endometrium can be a naturally expressed component or an exogenously incorporated component.
  • F is a molecule that mediates a cell-solute Interaction.
  • F is a ligand for a binding molecule where the presence of the binding molecule Is diagnostic for a pathological condition.
  • F is a ligand for an antibody (immunoglobulin),
  • the water soluble synthetic molecule construct has the structure: designated A ln -sp-Ad-DOPE (I); the structure: designated A tri -spsp 1 -Ad-DOPE (II); the structure: designated A tri -sp-Ad-DSPE (III); the structure designated B tri -sp-Ad-DOPE (VI); the structure: designated H tri -sp-Ad-DOPE ( VII ); the structure: designated H di -sp-Ad-DOPE ( VIII ); the structure: designated Galß 1 -sp-Ad-DOPE ( IX ); the structure: designated Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ); or the structure: designated Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ).
  • M is typically H, but may be replaced by another monovalent cation such as Na + , K + or NH 4 + .
  • the disclosure consists in a water soluble synthetic membrane anchor or synthetic molecule construct prepared by a method according to the second aspect of the disclosure.
  • the disclosure consists in a method of effecting qualitative and/or quantitative changes in the surface antigens expressed by a cell or multi-cellular structure including the step:
  • the cell or multi-cellular structure is of human or murine origin.
  • the concentration of the water soluble synthetic membrane anchor or synthetic molecule construct in the suspension is in the range 0.1 to 10 mg/mL.
  • the temperature is in the range 2 to 37 °C. More preferably the temperature is in the range 2 to 25 °C. Most preferably the temperature is in the range 2 to 4 °C.
  • the cell is a red blood cell.
  • F is selected from the group of glycotopes comprising the terminal sugars GalNAc ⁇ 1-3(Fuc ⁇ 1-2)Gal ⁇ ; Gal ⁇ 1-3Gal ⁇ ; Gal ⁇ ; Gal ⁇ 1-3(Fuc ⁇ 1-2)Gal ⁇ ; NeuAc ⁇ 2-3Gal ⁇ ; NeuAc ⁇ 2-6Gal ⁇ ; Fuc ⁇ 1-2Gal ⁇ ; Gal ⁇ 1-4GlcNAc ⁇ 1-6(Gal ⁇ 1-4GlcNAc ⁇ 1-
  • the cell is a red blood cell incorporating a water soluble synthetic membrane 3)Gal ⁇ ; Fuc ⁇ 1-2Gal ⁇ 1-4GlcNAc ⁇ 1-6(Fuc ⁇ 1-2Gal ⁇ 1-4GlcNAc ⁇ 1-3)Gal ⁇ ; Fuc ⁇ 1-2Gal ⁇ 1-4GlcNAc ⁇ 1-6(NeuAc ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-3)Gal ⁇ ; NeuAc ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-6(NeuAc ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-3)Gal ⁇ ; Gal ⁇ 1-4Gal ⁇ 1-4Glc; GalNAc ⁇ 1-3Gal ⁇ 1-4Gal ⁇ 1-4Glc; GalNAc ⁇ 1-3GalNAc ⁇ 1-3Gal ⁇ 1-4Gal ⁇ 1-4Glc; or GalNAc ⁇ 1-3GalNAc ⁇ 1-3Gal ⁇ 1-4Gal ⁇ 1-4Glc. More preferably F is selected from the group of glycotopes consisting of the oligosaccharides GalNAc ⁇ 1-3(Fuc ⁇ 1-2)
  • the synthetic molecule construct is selected from the group including: A tri -sp-Ad-DOPE ( I ); A tri -spsp 1 -Ad-DOPE ( II ); A tri -sp-Ad-DSPE ( III ); B tri -sp-Ad-DOPE ( VI ); H tri -sp-Ad-DOPE ( VII ); H di -sp-Ad-DOPE ( VIII ); Gal ⁇ i -sp-Ad-DOPE ( IX ); Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ); and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ).
  • the multi-cellular structure is a non-human embryo.
  • F is an attachment molecule where the attachment molecule has an affinity for a component expressed on the epithelial cells or the extra-cellular matrix of the endometrium.
  • the component expressed on the epithelial cells or the extra-cellular matrix of the endometrium can be a naturally expressed component or an exogenously incorporated component.
  • the synthetic membrane anchor or synthetic molecule construct is selected from the group including: A tri -sp-Ad-DOPE ( I ); A tri -spsp 1 -Ad-DOPE ( II ); A tri -sp-Ad-DSPE ( III ); B tri -sp-Ad-DOPE ( VI ); H tri -sp-Ad-DOPE ( VII ); H di -sp-Ad-DOPE ( VIII ); Gal ⁇ i -sp-Ad-DOPE ( IX ); Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ); and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ).
  • the cell is red blood cell.
  • F is a ligand for a binding molecule where the presence of the binding molecule is diagnostic for a pathological condition. More preferably F is a ligand for an antibody (immunoglobulin).
  • the disclosure consists in a cell or multi-cellular structure incorporating a water soluble synthetic membrane anchor or synthetic molecule construct according to the first or third aspect of the disclosure.
  • the cell or multi-cellular structure is of human or murine origin.
  • anchor or synthetic molecule construct selected from the group including: A tri -sp-Ad-DOPE ( I ); A tri -spsp 1 -Ad-DOPE ( II ); A tri -sp-Ad-DSPE ( III ); B tri -sp-Ad-DOPE ( VI ); H tri -sp-Ad-DOPE ( VII ); H di -sp-Ad-DOPE ( VIII ); Gal ⁇ i -sp-Ad-DOPE ( IX ); Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ); and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ).
  • the multi-cellular structure a non-human an embryo incorporating a water soluble synthetic membrane anchor or synthetic molecule construct selected from the group consisting of: A tri -sp-Ad-DOPE (I); A tri -spsp 1 -Ad-DOPE ( II ); A tri -sp-Ad-DSPE ( III ); B tri -sp-Ad-DOPE ( VI ); H tri -sp-Ad-DOPE ( VII ); H di -sp-Ad-DOPE ( VIII ); Gal ⁇ i -sp-Ad-DOPE ( IX ) ; Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ) ; and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ).
  • the invention consists in a kit comprising a dried preparation or solution of a water soluble synthetic membrane anchor or synthetic molecule construct according to the first or third aspect of the invention.
  • the synthetic membrane anchor or water soluble synthetic molecule construct according to the first or third aspect of the invention is selected from the group consisting of: A tri -sp-Ad-DOPE (I); A tri -spsp 1 -Ad-DOPE ( II ) ; A tri -sp-Ad-DSPE ( III ) ; B tri -sp-Ad-DOPE ( VI ); H tri -sp-Ad-DOPE ( VII ); H di -sp-Ad-DOPE ( VIII ); Gal ⁇ i -sp-Ad-DOPE ( IX ); Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ); and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ).
  • the invention consists in a kit comprising a suspension in a suspending solution of cells or multi-cellular structures according to the fifth aspect of the invention.
  • the suspending solution is substantially free of lipid.
  • the cell or multi-cellular structure is of human or murine origin.
  • the cells are red blood cells that do not naturally express A- or B-antigen and incorporate a water soluble synthetic membrane anchor or synthetic molecule construct selected from the group consisting of: A tri -sp-Ad-DOPE ( I ); A tri -spsp 1 -Ad-DOPE ( II ); A tri -sp-Ad-DSPE ( III ); B tri -sp-Ad-DOPE ( VI ); H tri -sp-Ad-DOPE ( VII ); H di -sp-Ad-DOPE ( VIII ); Gal ⁇ i -sp-Ad-DOPE ( IX ); Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ); and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-Ad-DOPE ( XIII ). More preferably the cells are sensitivity controls.
  • the invention consists in a pharmaceutical preparation comprising a dried preparation or solution of a water soluble synthetic membrane anchor or synthetic molecule construct according to the first or fourth aspect of the invention.
  • the pharmaceutical preparation is in a form for administration by inhalation.
  • the pharmaceutical preparation is in a form for administration by injection.
  • the disclosure consists in a pharmaceutical preparation comprising cells or multi-cellular structures according to the fifth aspect of the disclosure.
  • the cells or multi-cellular structures are of human or murine origin.
  • the pharmaceutical preparation is in a form for administration by inhalation.
  • the pharmaceutical preparation is in a form for administration by injection.
  • the synthetic molecule constructs of the invention spontaneously and stably incorporate into a lipid bi-layer, such as a membrane, when a solution of the molecule is contacted with the lipid bi-layer.
  • a lipid bi-layer such as a membrane
  • the synthetic molecule constructs identified herein have also been found to be water soluble.
  • the synthetic molecule constructs of the invention are used to transform cells resulting in qualitative and/or quantitative changes in the surface antigens expressed. It will be recognised that the transformation of cells in accordance with the invention is distinguished from transformation of cells by genetic engineering.
  • the invention provides for phenotypic transformation of cells without genetic transformation.
  • transformation in reference to cells is used to refer to the insertion or incorporation into the cell membrane of exogenously prepared synthetic molecule constructs thereby effecting qualitative and quantitative changes in the cell surface antigens expressed by the cell.
  • the synthetic molecule constructs of the disclosure comprise an antigen (F) linked to a lipid portion (or moiety) (L) via a spacer (S 1 -S 2 ).
  • the synthetic molecule constructs can be prepared by the condensation of a primary aminoalkyl, secondary aliphatic aminoalkyl or primary aromatic amine derivative of the antigen with an activated lipid. Methods of preparing neoglycoconjugates have been reviewed ( Bovin, N. Biochem. Soc. Symp., 69, 143-160 ).
  • a desired phenotypic transformation may be achieved using the synthetic molecule constructs of the invention in a one step method or a two step method.
  • the water soluble synthetic molecule construct (F-S 1 S 2 -L) comprises the surface antigen as F.
  • the synthetic molecule construct (F-S 1 -S 2 -L) comprises an antigen (F) that serves as a functional group to which a surface antigen can be linked following insertion of the synthetic molecule construct into the membrane.
  • the functional group can be a group such as a lectin, avidin or biotin.
  • the synthetic molecule construct is acting as a synthetic membrane anchor.
  • the primary aminoalkyl, secondary aliphatic aminoalkyl or primary aromatic amine and the activator of the lipid are selected to provide a synthetic molecule construct that is water soluble and will spontaneously and stably incorporate into a lipid bi-layer when a solution of the synthetic molecule construct is contacted with the lipid bi-layer.
  • water soluble means a stable, single phase system is formed when the synthetic molecule construct is contacted with water or saline (such as PBS) in the absence of organic solvents or detergents, and the term “solution” has a corresponding meaning.
  • stably incorporate means that the synthetic molecule constructs incorporate into the lipid bi-layer or membrane with minimal subsequent exchange between the lipid bi-layer or membrane and the external aqueous environment of the lipid bi-layer or membrane.
  • the selection of the primary aminoalkyl, secondary aliphatic aminoalkyl or primary aromatic amine and the activator depends on the physico-chemical properties of the antigen (F) to be linked to the lipid (L).
  • the structure of the spacer for synthetic molecule constructs (F-S 1 -S 2 -L) where F is a glycotope of the A-, B- and H-antigens of the ABO blood groups, may be the structure of the spacer selected to prepare synthetic molecule constructs of other antigens with physico-chemical properties similar to the glycotopes of the A-, B- and H-antigens of the ABO blood groups.
  • the glycotope of a broad range of blood group related glycolipids or glycoproteins could be the antigen (F) of the synthetic molecule construct F-S 1 -S 2 -L where S 1 -S 2 -L is identical or equivalent to the corresponding portion of the synthetic molecule constructs designated A tri -sp-Ad-DOPE ( I ), A tri -spsp 1 -Ad-DOPE ( II ), A tri -sp-Ad-DSPE ( III ), B tri -sp-Ad-DOPE ( VI ), H tri -sp-Ad-DOPE ( VII ), H di -sp-Ad-DOPE ( VIII ), Galß-sp-Ad-DOPE ( IX ), Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc ⁇ 1-3Gal ⁇ 1-4GlcNAc-sp-Ad-DOPE ( XII ), and Fuc ⁇ 1-2Gal ⁇ 1-3(Fuc ⁇ 1-4)GlcNAc-sp-s
  • Gl D-Gal
  • Gc D-Glc
  • GcN D-GlcNAc
  • M D-Man
  • F L-Fuc
  • NA NeuAc
  • the synthetic molecule constructs (F-S 1 -S 2 -L) of the invention where F is an oligosaccharide may be used as "synthetic glycolipids" and substituted for glycolipids obtained from biological (botanical or zoological) sources.
  • glycolipid means a lipid containing carbohydrate of amphipathic character including: glycosylated glycerolipids, such as glycosylated phosphoglycerides and glycosylglycerides; glycosylated sphingolipids (neutral glycolipids) such as glycosylceramides or cerebrosides; and gangliosides (acidic glycolipids).
  • glycosylated glycerolipids such as glycosylated phosphoglycerides and glycosylglycerides
  • glycosylated sphingolipids neutral glycolipids
  • glycosylceramides or cerebrosides such as glycosylceramides or cerebrosides
  • gangliosides acidic glycolipids
  • glycolipid-linked antigen means a lipid containing carbohydrate in which an antigen (e.g. a protein) is linked to the glycolipid via the carbohydrate portion of the molecule.
  • an antigen e.g. a protein
  • glycolipid-linked antigens include GPI-linked proteins.
  • glycolipid is itself an antigen.
  • glycolipid and glycolipid-linked antigen are used to distinguish between naturally occurring molecules where the antigen is the glycolipid and naturally occurring molecules where the antigen is linked to the glycolipid via the carbohydrate portion of the glycolipid.
  • synthetic molecule constructs of the invention could be described as both “synthetic glycolipids” and synthetic membrane anchors to the extent that the antigen may be the synthetic glycolipid per se or attached to the synthetic glycolipid.
  • carbohydrate portion of a glycolipid may be modified and linked to other antigens by the methods described in the specification accompanying the international application no. PCT/NZ2003/00059 (published as WO03087346 ).
  • glycotope is used to refer to the antigenic determinant located on the carbohydrate portion of a glycolipid.
  • the classification of glycolipid antigens in blood group serology is based on the structure of the carbohydrate portion of the glycolipid.
  • the terminal three sugars of the carbohydrate portion of the naturally occurring A- or B-antigen are the determinant of the A and B blood groupings.
  • the terminal four or five sugars of the carbohydrate portion of the naturally occurring A-antigen are the determinant of the A blood sub-groupings A type 1, A type 2, etc. Accordingly the RBCs incorporating the synthetic molecule constructs of the invention can be used to characterise and discriminate between blood typing reagents (antibodies) of differing specificity.
  • Water soluble synthetic molecule constructs of the invention that exclude a carbohydrate portion are contemplated by the inventors.
  • Antigens other than carbohydrates or oligosaccharides, but with similar physico-chemical properties, may be substituted for F in the "synthetic glycolipids" described.
  • Synthetic molecule constructs of the invention that comprise an antigen (F) with differing physico-chemical properties to those of carbohydrates or oligosaccharides are also contemplated by the inventors. Water soluble synthetic molecule constructs comprising these antigens may be prepared by selecting different spacers.
  • the synthetic molecule constructs overcome many of the limitations of using natural glycolipids in the practice of these inventions.
  • a particular advantage of the synthetic molecule constructs is their superior performance and ability to be used in the transformation of cells at reduced temperatures, e.g. 4°C.
  • a tri -sp-lipid ( IV ) and Atri-PAA-DOPE (V) were determined not to be water soluble and/or unable to spontaneously and stably incorporate in to a lipid bilayer such as a cell membrane.
  • the Comparative Examples do not form part of the invention claimed.
  • the Comparative Examples describe red blood cell transformation with natural glycolipids.
  • Glycolipids were separated on silica gel with a mobile phase of increasing polarity.
  • the program was a linear gradient beginning with 100% chloroform-methanol-water 80:20:1 (v/v) and ending with 100% chloroform-methanol-water 40:40:12 (v/v).
  • the HPLC equipment used was a Shimadzu system capable of pumping and mixing four separate solvents at programmed ratios. As chloroform, methanol and water evaporate at different rates, a program was developed whereby the solvent components were not mixed prior to entering the HPLC.
  • the Shimadzu HPLC mixes four different liquids by taking a "shot” from each of four bottles in turn. "Shots" of chloroform and water directly next to each other in the lines may cause miscibility problems. Methanol was sandwiched in between these two immiscible components. Additionally, the water was pre-mixed with methanol in a 1:1 ratio to further prevent problems with miscibility.
  • the Diamed system proved to be more sensitive to the weaker reactions than tube serology with the Seraclone anti-A, but not with Albaclone.
  • These reagents are formulated differently, and are thus not expected to perform identically.
  • the fact that the Seraclone anti-A tube serology combination did not detect positivity is probably due to operator interpretation.
  • the weaker reactions are notoriously difficult to accurately score, and the difference between 1+ and 0 can be difficult to discern in tubes.
  • the A glycolipid sample contained other lipid impurities and thus comparatively less blood group A molecules by weight than the Le b glycolipid sample of equivalent concentration (w/v). This seems to be borne out by the fact that higher concentrations of the A glycolipid than the Le b glycolipid were required to produce equivalent agglutination scores (see Table 6).
  • the level of impurity in the A glycolipid sample may also have contributed to the lower stability over the 62 day period - the A-transformed cells 'died' at the highest concentration (having received the largest dose of impurity).
  • Table 5 Anti-A and anti-Le b used in initial testing of natural glycolipid transformation. Manufacturer Catalogue ref Batch number Expiry Anti-A Seraclone, Biotest 801320100 1310401 12.04.03 Anti-Le b CSL 12801 Table 6. Stability of RBCs transformed with natural A and Le b glycolipid as assessed by tube serology agglutination over the period of 62 days.
  • Glycolipid (mg/mL) Le b A Day 1 Day 25 Day 62 Day 1 Day 25 Day 62 10 4+ 2-3+ 3+ 2+ ? 5 4+ 2-3+ 2+ 2+ w+ 2 3+ 1-2+ 0 1+ 0 1 4+ 2+ 0 1+ 0 0.1 3+ 2+ 0 0 0.01 2+ 2+ 0 0 0.001 2+ 2+ 0 0 0.0001 2+ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  • the Le b sample was highly purified - before being dissolved, it was a powder of pure white colour, and thus it is unlikely that the haemolysis was due to the deleterious effect of impurities. It is clear to see that at 62 days, the amount of haemolysis occurring diminishes in line with the decrease in the glycolipid concentration.
  • Glycolipid Concentration (mg/mL) Albaclone BioClone 1 hour 2 hours 1 hour 2 hours A 10 4+ 4+ 4+ 4+ 5 4+ 4+ 4+ 2+ 2 4+ 3+ 3+ 2+ 1 3+ 2+ 2+ 2+ 0.5 2+ 2+ 1+ w+ B 10 3+ 2+ 4+ 1+ 5 3+ 2+ 3+ 2+ 2 2+ 2+ 1+ 1 1+ w+ 1+ w+ 0.5 1+ w+ w+ w+ w+
  • Two sets of cells were transformed with different concentrations of natural A glycolipid. Transformation was performed at 25°C. One set of cells was tested long term, and one set of cells was tested weekly for agglutination. The agglutination results from tube serology and Diamed are shown in Table 16 below. All cells were stored in CellstabTM in bottles with flat bases. The cells showed minimal to no haemolysis at any time. Table 16. Agglutination results for cells transformed with different concentrations of natural A glycolipid. Results were obtained using Albaclone anti-A.
  • CelpresolTM CSL
  • CellstabTM CellstabTM
  • a and B antisera from two different sources were used in serology testing.
  • Diamed gel-card testing was carried out to day 56 for the Alsevers stored cells, and discontinued at day 63 due to fungal contamination (although still returning positive scores).
  • the CellstabTM stored cells continued to be tested up to day 70, and were still viable at this point (see Figure 1 for A results and Figure 2 for B results).
  • Reactivity was determined by FACS analysis using a Gamma anti-Leb. (The serological detection level is around 10 2 molecules. The insertion of natural glycolipids at 4°C for 8 hours was not detectable by agglutination with antibodies.) Projection of the rate of insertion curve from FACS analysis did not indicate that the rate of insertion at 4°C would have reached agglutination detection levels within 24 hours.
  • the rate of transformation is slow for both natural A glycolipid and natural B glycolipid as demonstrated by the negative agglutination scores after 1 hour at 2°C. Considerable insertion at 37°C for this time interval has been demonstrated.
  • Natural A glycolipid insertion at 2°C required 48 hours to reach the same level of insertion obtainable by transformation at 37°C. After this time further insertion was not observed. Likewise, natural B glycolipid insertion at 2°C was not as rapid as transformation at 37°C. The agglutination scores did not improve upon continued incubation and thus seemed to have reached maximal insertion at this time point for these concentrations.
  • the Sug may be either the aminopropyl glycoside (F-S 1 -NH 2 ) of either GalNAc ⁇ 1-3(Fuc ⁇ 1-2)Galß trisaccharide (A-glycotope) (F) or Gal ⁇ 1-3(Fuc ⁇ 1-2)Galß trisaccharide (B-glycotope) (F).
  • the synthetic glycolipid must also be able to insert into the membrane and be recognisable to the appropriate antibody for transformation to be detected by agglutination. Initial tests on the molecules were to establish solubility and thus eliminate those molecules that were unsuitable for use in the transformation of cells.
  • DOPE Lipid Tails B tri -sp-Ad-DOPE ( VI) A tri -sp-Ad-DOPE (I) Gal ⁇ -sp-Ad-DOPE (IX) H di -sp-Ad-DOPE (VIII) H tri -sp-Ad-DOPE (VII) A tri -spsp1-Ad-DOPE (II) Btri-PAA-DOPE (V) Different Lipid Tails: A tri -Sp-lipid (IV) A tri -sp-Ad-DSPE (III) Table 22. Solubility of synthetic glycolipids in hot PBS and transformation ability.
  • the low rate of insertion of the natural glycolipids may be due to the physicochemical properties of the natural glycolipid tail; a sphingolipid and a fatty acid.
  • the diacyl tail of the glycolipid may be important in determining the rate of insertion. Certain diacyl tails may retain greater fluidity at lower temperatures. Alternatively, the domain of the plasma membrane into which the diacyl tail of these glycolipids inserts may retain this greater fluidity.
  • CelpresolTM was added to the cells so that the final cells:non-cells ratio was 3:5 (v/v). The cells continued to be tested at intervals. Testing was discontinued after 10 days because cells turned brown.
  • the post-transformation supernatant solutions (from A tri -sp-Ad-DOPE (I) at 0.08 mg/mL, 0.05 mg/mL and 0.03 mg/mL, and B tri -sp-Ad-DOPE (VI) at 0.6 mg/mL, 20 ⁇ L) were added neat and in a 1:2 dilution to washed, packed RBCs (60 ⁇ L). The tubes were incubated in a 37°C waterbath for one hour, with mixing taking place every 15 minutes.
  • post-transformation solutions were concentrated 20x and compared in parallel with the transformation solutions of known concentration. Only the post-transformation solutions derived from the 0.08 mg/mL A tri -sp-Ad-DOPE (I) and 0.6 mg/mL B tri -sp-Ad-DOPE (VI) solutions were tested.
  • Post-transformation solutions (20 ⁇ L) were dialysed (pore size 500Da) against de-ionised water for 2 days. The samples were left to dry in a fumehood for 10 days. At the end of this time they were transferred into a rotavapor flask and set on the rotavapor to rotate under vacuum with no heat overnight.
  • the post-transformation solutions (from A tri -sp-Ad-DOPE (I) at 0.08 mg/mL and B tri -sp-Ad-DOPE (VI) at 0.6 mg/mL, 20 ⁇ L) were added to washed, packed RBCs (60 ⁇ L).
  • the transformation solutions (A tri -sp-Ad-DOPE (I) at 0.08 mg/mL, 0.05 mg/mL and 0.03 mg/mL, and B tri -sp-Ad-DOPE (VI) at 0.6 mg/mL, 20 ⁇ L) were added to washed, packed RBCs (60 ⁇ L).
  • Diamed serology conc Score A tri -sp-Ad-DOPE (I) at 0.08 3+ A tri -sp-Ad-DOPE (I) at 0.05 2+ A tri -sp-Ad-DOPE (I) at 0.03 1+ From A tri -sp-Ad-DOPE ( I ) at 0.08 0 B tri -sp-Ad-DOPE (VI) at 0.60 4+ From B tri -sp-Ad-DOPE (VI) at 0.60 0
  • Example 8 RBC transformation with A- and B-antigen synthetic glycolipids with different non-carbohydrate structures
  • the water soluble synthetic glycolipids designated A tri -sp-Ad-DOPE (I), A tri -sp 1 sp 2 -Ad-DOPE (II), A tri -sp-Ad-DSPE (III), and B tri -sp-Ad-DOPE (VI) were prepared according to the method described in Example 1 with necessary modifications.
  • Washed packed group O red blood cells (3 parts by volume) and the synthetic glycolipid solution (1 part by volume, varying concentrations) were added to an eppendorf tube. The tube was incubated in a 37°C waterbath for one hour, mixing every 15 minutes. The transformed RBCs were washed 3x with PBS and then suspended in CellstabTM at the appropriate concentration for serology testing.
  • Tube serology and Diamed gel-card results for RBCs transformed with the different synthetic molecule constructs are provided in Table 38.
  • Results for the stability of the RBCs transformed with the different synthetic glycolipids at different concentrations are provided in Tables 39 to 44.
  • the water soluble synthetic glycolipids designated H tri -sp-Ad-DOPE (VII), H di -sp-Ad-DOPE (VIII) and Gal ⁇ -sp-Ad-DOPE (IX) were prepared according to the method described in Example 1 with necessary modifications.
  • Washed packed mouse RBCs (3 parts by volume) and the synthetic glycolipid solutions (1 part by volume of varying concentrations) were added to an eppendorf tube. The tube was incubated in a 37°C waterbath for one hour, mixing every 15 minutes. The transformed RBCs were washed 3x with PBS and then suspended in CellstabTM at the appropriate concentration for serology testing.
  • Tube serology and Diamed gel-card results for RBCs transformed with the different synthetic glycolipids are presented in Table 46.
  • the results show that three sugars (H tri ) are required for detection by anti-H IgM, at least by the reagent used.
  • Antisera Manufacturer Batch Anti-H IgM Japanese Red Cross HIRO-75 UEA Lorne Laboratories 11549E D.O.E.06.2004 Bio-UEA EY Labs 201105-2 Table 46. Comparison of transformation of RBCs using H-antigen synthetic glycolipids with different glycotopes made to different concentrations.
  • the water soluble synthetic glycolipids designated H di -sp-Ad-DOPE (VIII) and Gal ⁇ -sp-Ad-DOPE (IX) were prepared according to the method described in Example 1 with necessary modifications.
  • Murine RBCs were washed 3x in 1x PBS.
  • 30 ⁇ l of packed RBCs were combined with 30 ⁇ l of H di -sp-Ad-DOPE (VIII), and 30 ⁇ l of packed RBCs were combined with 30 ⁇ l Galß-sp-Ad-DOPE (IX), respectively.
  • Both synthetic molecule constructs were at a concentration of 1.0 mg/ml.
  • 30 ⁇ l of 1x PBS was added to 30 ⁇ l of packed RBCs to act as the control group.
  • Cells were incubated for 90 minutes in a 37°C shaking water-bath.
  • RBCs were washed 3x in 1x PBS.
  • the synthetic glycolipids of the invention may be used in the preparation of "sensitivity controls” (also referred to as “quality control cells”, “serology controls”, or “process controls”) as described in the specification accompanying international application no. PCT/NZ02/00214 ( WO 03/034074 ).
  • the synthetic glycolipids provide the advantage that the transformation of the RBCs may be achieved at reduced temperatures.
  • Glycolipids are manufactured in a white dry powder. Glycolipids in this form (enclosed in a sealed container under a controlled temperature) are stable for an indefinite period of time. The glycolipids are suspended in solution (e.g. Celpresol) by weight in order to formulate the transformation solutions.
  • solution e.g. Celpresol
  • transformation solutions are received at CSL, they are filtered (through a MILLEX®-GV 0.22 ⁇ filter unit) under aseptic conditions.
  • RBC donations are processed using a continuous flow centrifuge washer under aseptic conditions. RBC donations are washed in buffered saline followed by CelpresolTM solution. The PCV of the RBC donations is measured on a Beckman Coulter AcT Diff analyser. The donations are then adjusted to a packed cell volume (PCV) of 50% with the addition of CelpresolTM.
  • PCV packed cell volume
  • RBCs are washed in buffered saline and CelpresolTM.
  • the cells are suspended in CelpresolTM solution to a PCV of > 50%.
  • the PCV of red cells is measured using a Beckman Coulter AcT Diff.
  • the mass of the red cell solution is weighed.
  • red cell sample Incubate the red cell sample for 3 hours at 2-8°C under controlled temperature conditions and constant gentle agitation for 18 hours. At the end of the 3 hour period, aseptically remove a sample of red cells and test the sample to confirm transformation of the red cells. Perform blood grouping using tube, tile and CAT techniques.
  • the plasma may contain monoclonal and polyclonal antibodies. Antibodies are selected according to the desired characteristics of the sensitivity controls.
  • the plasma may additionally contain tartrazine and bovine serum albumin.
  • Blood grouping and antibody screening is performed on the bulk samples using tube, tile and CAT techniques.
  • the transformed RBC-SPD blend is then aseptically dispensed into BD Vacutainer tubes and the tubes labelled accordingly.
  • Weak AB cells produced by the use of synthetic glycolipids (designated A w B w in Tables 51 to 53) were used to validate a range of testing platforms in parallel with naturally occurring weak A, weak B and weak AB cells.
  • Table 49 Reagents and cards used in validation testing.
  • the synthetic molecules may be used as synthetic membrane anchors and/or synthetic molecule constructs. Therefore, they may also be employed in the method of enhancing embryo implantation as described in international patent application no PCT/NZ2003/000059 (published as WO 03/087346 ) which is incorporated by reference.
  • a single cell suspension of endometrial epithelial cells was prepared.
  • the endometrial cells were washed 3x by resuspending in CMF HBSS and centrifuging at 2000 rpm for 3 minutes.
  • the washed cell preparation was resuspended in 50 ⁇ l of M2.
  • Micro-centrifuge tubes each containing a 50 ⁇ l solution of 5M/ml endometrial cells were prepared.
  • 50 ⁇ l of synthetic glycolipids A tri -sp-Ad-DOPE ( I ) or B tri -sp-Ad-DOPE A ( VI ), or 50 ⁇ l M2 were added to the control cells.
  • the cells were incubated for 90 minutes at 37°C on a mixer.
  • the endometrial cells were washed 3x by resuspending in CMF HBSS media and centrifuging at 2000 rpm for 3 minutes.
  • the washed cell preparation was resuspended in 50 ⁇ l of M2.
  • the embryo zona pellucida was removed by treating embryos with 0.5% pronase in a 37°C oven for 6 minutes or until all zonas were removed.
  • Micro-drops were prepared by adding 5 ⁇ l of synthetic glycolipid A tri -sp-Ad-DOPE (I) or B tri -sp-Ad-DOPE ( VI ), at a concentration of 1 mg/mL to a 45 ⁇ l drop of M2 media overlaid with mineral oil. All embryo groups were incubated in the 50 ⁇ l micro-drops for 1 hour at 37°C. Embryos from experimental and control groups were washed 3x with M2 media.
  • Embryos from experimental and control groups were placed into a micro-drop of corresponding antibody and incubated for 30 min at 37°C. Embryos from experimental and control groups were washed 3x with M2 media.
  • Embryos from all experimental and control groups were placed into micro-drops of anti-mouse Ig FITC (1:50 dilution anti-mouse Ig FITC in M2) and incubated for 30 min at 37°C. Embryos from experimental and control groups were washed 3x with M2 media. Embryos were mounted on microscope slides in a 5 ⁇ l drop of M2 and the drops overlaid with oil.
  • Cell Type Inserted Antigen 1 antibody Fluorescence score after incubation with IgFITC Probe Embryo Morphology 24hr post insertion Embryos A tri -Sp-Ad-DOPE ( I ) Anti-A Bioclone 2+ n.d.
  • Embryos Control M2 media) Anti-A Bioclone 0 n.d. Abbreviations: n.d. Not determined
  • Two concave glass slides were prepared, one with two wells of synthetic glycolipid A tri -sp-Ad-DOPE (I) inserted endometrial cells and the other with two wells of synthetic glycolipid B tri -sp-Ad-DOPE ( VI ) inserted endometrial cells.
  • the embryos were surrounded with endometrial cells.
  • the wells were covered with mineral oil and incubated for 15 minutes at 37°C.
  • each group of embryos were carefully transferred to a fresh drop of M2 media.
  • the embryos were gently washed.
  • the embryos were gently transferred into 2 ⁇ L of M2 media on a marked microscope slide. Each drop was overlaid with mineral oil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05722123.6A 2004-03-22 2005-03-22 Synthetic membrane anchors Active EP1735323B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ53186604 2004-03-22
NZ53794105 2005-01-28
PCT/NZ2005/000052 WO2005090368A1 (en) 2004-03-22 2005-03-22 Synthetic membrane anchors

Publications (3)

Publication Number Publication Date
EP1735323A1 EP1735323A1 (en) 2006-12-27
EP1735323A4 EP1735323A4 (en) 2009-11-04
EP1735323B1 true EP1735323B1 (en) 2017-08-30

Family

ID=34993634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05722123.6A Active EP1735323B1 (en) 2004-03-22 2005-03-22 Synthetic membrane anchors

Country Status (12)

Country Link
US (5) US8013131B2 (zh)
EP (1) EP1735323B1 (zh)
JP (1) JP5456250B2 (zh)
CN (1) CN1938325B (zh)
AU (3) AU2005223715A1 (zh)
CA (1) CA2560781C (zh)
DK (1) DK1735323T3 (zh)
EA (1) EA013183B1 (zh)
ES (1) ES2654578T3 (zh)
IL (1) IL178008A (zh)
NZ (2) NZ550705A (zh)
WO (1) WO2005090368A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550705A (en) 2004-03-22 2010-12-24 Kode Biotech Ltd Synthetic membrane anchors
WO2008030115A2 (en) * 2006-09-06 2008-03-13 Elena Korchagina Fluorescent cell markers
US10858384B2 (en) 2004-03-22 2020-12-08 Kode Biotech Limited Synthetic molecule constructs
AU2011202876B2 (en) * 2006-09-06 2011-09-01 Kode Biotech Limited Fluorescent cell markers
US20080160003A1 (en) * 2006-10-31 2008-07-03 University Of Delaware Fertility Enhancement Using Lipid Carriers and Bioactive Molecules
US8211860B2 (en) 2007-04-27 2012-07-03 Kode Biotech Limited Carbohydrate-lipid constructs and their use in preventing or treating viral infection
CN101918841B (zh) * 2007-09-11 2013-09-11 科德生物工程有限公司 肽-脂构造及其在诊断和治疗用途中的应用
WO2009035347A1 (en) 2007-09-11 2009-03-19 Cristina-Simona Weinberg Peptide-lipid constructs and their use in diagnostic and therapeutic applications
US10919941B2 (en) 2007-10-12 2021-02-16 Kode Biotech Limited Functional lipid constructs
AU2013201431B2 (en) * 2007-10-12 2015-02-19 Kode Biotech Limited Functional lipid constructs
DK2201025T3 (en) 2007-10-12 2016-06-27 Kode Biotech Ltd functional lipidkonstruktionsprodukter
US11052141B1 (en) 2008-10-02 2021-07-06 Kode Biotech Limited Method of modifying the immune response
WO2010039049A1 (en) * 2008-10-02 2010-04-08 Kode Biotech Limited Method of modifying the immune response
CA2740554C (en) 2008-10-13 2016-12-20 Nikolai Vladimirovich Bovin Multiligand constructs
AU2010266797B2 (en) * 2009-06-29 2013-10-03 Nicolai Vladimirovich Bovin Printing of FSL constructs
US10408717B2 (en) 2009-06-29 2019-09-10 Nicolai Vladimirovich Bovin Printing of FSL constructs
GB2500854B (en) * 2011-01-06 2019-04-17 Vladimirovich Bovin Nicolai Biosurface engineering
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP4170031A1 (en) 2012-10-23 2023-04-26 Caris Science, Inc. Aptamers and uses thereof
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
US9814786B2 (en) 2013-12-02 2017-11-14 Nicolai Bovin Functionalizing nanofibres
NZ732618A (en) 2014-11-21 2020-10-30 Stephen Micheal Henry Multivalent ligand-lipid constructs
US10544842B2 (en) * 2017-03-24 2020-01-28 Ford Global Technologies, Llc One-way clutch for a vehicle
BR112020023955A2 (pt) 2018-05-27 2021-02-23 Biolinerx Ltd. agi-134 combinado com um inibidor de ponto de controle para o tratamento de tumores sólidos

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334583A (en) 1982-07-23 1994-08-02 Ciba-Geigy Corp. Use of sugar derivatives for the prophylaxis and treatment of virus infections
EP0102319B1 (de) * 1982-07-23 1987-08-19 Ciba-Geigy Ag Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen
US4622294A (en) 1985-02-08 1986-11-11 Kung Viola T Liposome immunoassay reagent and method
US4873322A (en) * 1986-01-24 1989-10-10 Ciba-Geigy Corporation Saccharide derivatives and processes for their manufacture
IT1229514B (it) * 1989-01-30 1991-09-03 Farmhispania S A A Montme Glicoconiugati anfifilici sintetici per impiego neurologico.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP3408271B2 (ja) 1992-07-17 2003-05-19 生化学工業株式会社 糖のアミノ化法
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5344583A (en) * 1993-08-26 1994-09-06 Dotolo Research Corp. Composition for removing nail enamel from artificial nails
JP3942205B2 (ja) 1995-07-24 2007-07-11 生化学工業株式会社 神経疾患の治療剤
DE19624345B4 (de) 1996-06-19 2004-12-23 Südzucker AG Mannheim/Ochsenfurt Acylierte Kohlenhydrate mit mindestens einer mit dem Kohlenhydrat veretherten Carboxyalkyl-Gruppe, Verfahren zu deren Herstellung und deren Verwendung in Waschmitteln
US5973128A (en) 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
AU8505398A (en) 1997-07-23 1999-02-16 Northeastern University Methods for enhancing or reducing preimplantation embryo survival rates
US5962423A (en) 1998-08-07 1999-10-05 The Governors Of The University Of Alberta Treatment of bacterial dysentery
AU1861001A (en) 1999-11-29 2001-06-12 Syntesome Gesellschaft Fur Medizinische Biochemie Mbh Arrays of glycan molecules (glycoarrays) on the surface of biochips (glycochips)and uses thereof
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US20060189568A1 (en) 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
CA2397016C (en) 2000-01-10 2011-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
EP2286843A3 (en) * 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
US6949663B2 (en) 2000-11-10 2005-09-27 Japan Science And Technology Corporation Carboxylic acid-type lipid
EP1442305B1 (en) 2001-10-16 2009-09-30 Kode Biotech Limited Sensitivity controls for blood serology prepared from modified cells
NZ518163A (en) * 2002-04-05 2005-04-29 Kiwi Ingenuity Ltd Embryo modified with a glycolipid to enhance implantation into the endometrium
WO2004045583A1 (ja) * 2002-11-15 2004-06-03 Nipro Corporation リポソーム
WO2005049631A1 (en) * 2003-11-18 2005-06-02 The Malaghan Institute Of Medical Research Synthetic molecules having immune activity
NZ550705A (en) 2004-03-22 2010-12-24 Kode Biotech Ltd Synthetic membrane anchors
JP4639055B2 (ja) 2004-05-20 2011-02-23 公益財団法人野口研究所 ベロ毒素中和剤としてのスフィンゴ糖脂質類似体
JP2006241095A (ja) 2005-03-04 2006-09-14 National Univ Corp Shizuoka Univ フィラグリン合成促進剤および紫外線傷害緩和剤
EP1926742B1 (en) 2005-09-21 2016-12-28 Kode Biotech Limited Cell surface coating with hyaluronic acid oligomer derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
IL178008A (en) 2011-10-31
US9809614B2 (en) 2017-11-07
AU2010203098B2 (en) 2012-07-12
US20110213134A1 (en) 2011-09-01
US8637473B2 (en) 2014-01-28
AU2010203099B2 (en) 2012-12-06
AU2010203098A1 (en) 2010-08-12
CN1938325B (zh) 2015-07-15
US9353349B2 (en) 2016-05-31
CA2560781A1 (en) 2005-09-29
US20070197466A1 (en) 2007-08-23
ES2654578T3 (es) 2018-02-14
US8013131B2 (en) 2011-09-06
US20140186950A1 (en) 2014-07-03
EP1735323A1 (en) 2006-12-27
CA2560781C (en) 2011-10-11
US10414786B2 (en) 2019-09-17
CN1938325A (zh) 2007-03-28
DK1735323T3 (en) 2017-12-11
US20180057518A1 (en) 2018-03-01
AU2005223715A1 (en) 2005-09-29
NZ587442A (en) 2012-02-24
NZ550705A (en) 2010-12-24
EA200601753A1 (ru) 2007-04-27
WO2005090368A1 (en) 2005-09-29
EA013183B1 (ru) 2010-02-26
US20160333044A1 (en) 2016-11-17
JP2007530532A (ja) 2007-11-01
AU2010203099A1 (en) 2010-08-12
JP5456250B2 (ja) 2014-03-26
EP1735323A4 (en) 2009-11-04
IL178008A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
EP1735323B1 (en) Synthetic membrane anchors
Stroud et al. Monosialogangliosides of human myelogenous leukemia HL60 cells and normal human leukocytes. 2. Characterization of E-selectin binding fractions, and structural requirements for physiological binding to E-selectin
Handa et al. Carbohydrate to carbohydrate interaction in development process and cancer progression
EP2201025B1 (en) Functional lipid constructs
Yoshizaki et al. Role of glycosphingolipid-enriched microdomains in innate immunity: microdomain-dependent phagocytic cell functions
Stocker et al. Chemical tools for studying the biological function of glycolipids
EP2255787A1 (en) Synthetic glycolipid-containing liposomes
Kniep et al. Subcellular localization of glycosphingolipids in human neutrophils
SUZUKI et al. Heterophile antibodies to rabbit erythrocytes in human sera and identification of the antigen as a glycolipid
US10858384B2 (en) Synthetic molecule constructs
Chou et al. Expression of neolactoglycolipids: sialosyl-, disialosyl-, O-acetyldisialosyl-and fucosyl-derivatives of neolactotetraosyl ceramide and neolactohexaosyl ceramide in the developing cerebral cortex and cerebellum
Endo et al. Intermolecular interaction between glycolipids and glycophorin on liposomal membranes
AU2008297660A1 (en) Peptide-lipid constructs and their use in diagnostic and therapeutic applications
US10919941B2 (en) Functional lipid constructs
US11052141B1 (en) Method of modifying the immune response
Marcus My career as an immunoglycobiologist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KODE BIOTECH LIMITED

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091001

17Q First examination report despatched

Effective date: 20110916

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602005052623

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07F0009117000

Ipc: C07F0009100000

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 15/04 20060101ALI20160120BHEP

Ipc: A61P 43/00 20060101ALI20160120BHEP

Ipc: A61K 31/685 20060101ALI20160120BHEP

Ipc: C12N 5/00 20060101ALI20160120BHEP

Ipc: C07F 9/10 20060101AFI20160120BHEP

Ipc: A61K 31/7032 20060101ALI20160120BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160329

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170210

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTC Intention to grant announced (deleted)
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

INTG Intention to grant announced

Effective date: 20170721

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 923443

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005052623

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20171206

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170830

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 923443

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2654578

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171201

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171230

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005052623

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050322

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230910

Year of fee payment: 19

Ref country code: GB

Payment date: 20230910

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240320

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240321

Year of fee payment: 20

Ref country code: DK

Payment date: 20240326

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240426

Year of fee payment: 20